AKD’s Top 3 Pharma Picks For 2026
2. Haleon Pakistan Limited (HALEON)
Haleon Pakistan Limited remains one of the most dominant consumer healthcare companies in Pakistan due to its category-leading brands, strong returns profile, and ongoing manufacturing transformation.
Brand Leadership Continues To Drive Revenue Stability
The company owns several of Pakistan’s most recognizable healthcare brands, including Panadol, Sensodyne, and CaC-1000 Plus. Panadol controls more than 40% market share within analgesics, while Sensodyne commands over 70% share in oral care. CaC-1000 Plus maintains nearly 30–35% share within bone and joint health products. Together, these three brands contribute nearly 80% to 88% of total company sales, providing strong revenue visibility even during periods of economic volatility.
📢 Announcement: You can now access our services and similar analyses by opening an account with us via JS Global
Don't miss:
- Top 5 Analyst Questions From Lucky Core Industries (LCI) Corporate Briefing
- 5 Reasons Why MEBL Could Continue Rising Despite a Growth Slowdown
- AKD Predicts PSO Could Double From Here
Jamshoro Expansion Could Improve Margins Further
One of the company’s biggest operational shifts for 2026 is the expansion of the Jamshoro manufacturing facility. Management is bringing Panadol manufacturing in-house, reducing outsourced production from 36% of the portfolio to only 4%. This transition is expected to materially lower cost structures and improve gross margins. By the end of CY26, solid drug capacity is expected to increase from 30 million units to 50 million units, while vitamin production capacity is projected to rise from 52 million units to 79 million units.
Wellness Segment Is Becoming More Important
The company expanded further into wellness products through the launch of Centrum Adult and Centrum Silver. Management is currently pursuing regulatory approvals for local manufacturing, which could reduce import costs and improve profitability over time.
Export Expansion Supports Diversification
Haleon is actively developing export channels across 18–19 international markets, primarily across Southeast Asia and Africa. Exporting products such as Panadol and CaC-1000 also provides additional FX-linked revenue exposure, helping diversify earnings beyond the domestic market. The company continues to maintain one of the sector’s strongest return profiles with Return on Equity standing at 47%, supported by nearly PKR 6 billion in cash reserves allocated toward facility upgrades and dividends.
📢 Announcement: We're on WhatsApp – Join Us There!
⚠️ This post reflects the author’s personal opinion and is for informational purposes only. It does not constitute financial advice. Investing involves risk and should be done independently. Read full disclaimer →
Comment (1)
The article’s focus on the shift toward structurally higher profitability driven by chronic therapy exposure and export diversification is a key insight for 2026. Highlighting GlaxoSmithKline Pakistan alongside Highnoon and Haleon effectively illustrates how dominant brands and margin recovery are becoming critical metrics in this sector.